NCT00731211

Pazopanib in Previously Treated Patients With Metastatic Renal Cell Carcinoma

A Phase II Trial of Pazopanib in Patients With Metastatic Renal Cell Carcinoma Previously Treated With Sunitinib or Bevacizumab

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 57 (actual)
• Sponsor: SCRI Development Innovations, LLC · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a Phase II, non-randomized, open-label, single-arm study in patients with metastatic renal cell carcinoma who have received one prior targeted therapy with either sunitinib or bevacizumab. The planned enrollment for this study is 60 patients.

Detailed description

All eligible patients will receive 800 mg of pazopanib orally each day continuously. Patients will be re-evaluated for treatment response after 8 weeks of daily oral pazopanib therapy. Response to therapy will be assigned using RECIST criteria (Section 6.0) Patients who have objective response or stable disease will continue treatment with evaluations every 8 weeks, until the time of tumor progression or intolerable treatment-related side effects.

Conditions

• Renal Cell Carcinoma

Interventions

Type	Name	Description
DRUG	Pazopanib	800 mg of pazopanib orally each day continuously

Timeline

• Start date: 2008-09-01
• Primary completion: 2011-05-01
• Completion: 2012-09-01
• First posted: 2008-08-08
• Last updated: 2015-05-20
• Results posted: 2015-05-20

Locations

17 sites across 1 country: United States